Pharminent

NICE backs use of Forxiga in triple therapy for diabetes

The National Institute for Health and Care Excellence has now published final draft guidelines endorsing NHS use of AstraZeneca’s Forxiga for treating type II diabetes as part of a ‘triple therapy’. http://www.pharmatimes.com/news/nice_backs_use_of_forxiga_in_triple_therapy_for_diabetes_1155532

Filed under: Diabetes, SGLT-2